Abstract:The accuracy of information retrievable from the memories of DDDR pacing systems has been limited by the absence of actual electrograms confirming the proper sensing of spontaneous cardiac activity versus that of extraneous signals. This study examined the diagnostic power of a new arrhythmia interpretation scheme, which includes the recording and storage of high resolution endocavitary atrial and ventricular electrograms (HREGM). HREGM stored in the memories of new generation pacemakers (PM) in response to no… Show more
“…Israel et al confirmed AT in 35% (83 of 235) of stored mode switch episodes in 46 patients (Pulsar VDD, Guidant) 12 . Defaye et al reported appropriate detection of atrial arrhythmias in 34% of 206 stored episodes from 70 of 520 patients using a variety of devices (Guidant Discovery 1274, Pulsar 972, Pulsar Max 1270) 13 . Bordacher et al 14 reported inappropriate mode switch detection due to FFRW oversensing in 20% of 3,511 mode‐switch episodes from 137 patients (Talent DR213 PM, ELA Medical, Montrouge, France).…”
The clinical application of atrial tachyarrhythmia (AT) episode data stored by implantable devices is presently limited by the high proportion of inappropriate detection. We quantified the percentage of inappropriate AT detection in two implantable devices with AT diagnostics and therapies via meta-analysis of stored AT episodes from a number of clinical trials. The AT500 and GEM III AT, contain dual chamber logic to discriminate AT from ventricular tachycardia and far-field R wave (FFRW) oversensing using dual chamber bipolar electrograms. A subset of data from four clinical trials of 1,142 patients was considered. Manual analysis was performed on 21,553 stored episodes with atrial EGM and marker channel from 409 patients with stored episodes and the market-released device detection configuration. The percentage of episodes with inappropriate detection and termination was evaluated and compared between septal and nonseptal lead locations. The percentage of inappropriately detected episodes receiving ATP therapy was also determined. The percentage of episodes appropriately detected and the percentage of net episode duration (i.e., burden) recorded by the device were also determined from a separate analysis of 24-hour Holter recordings from a subset of 40 patients from one trial. Adjusted estimates of the percentage of appropriate [corrected] detection were 95.3% (93.5-96.7; 95% CI) for AT500 and 95.7% (84.3-98.9) for GEM III AT. Inappropriate detection was primarily due to FFRW oversensing or brief runs of premature atrial contractions (PACs). The device detected 100% of the sustained atrial arrhythmia episodes and 95.3% (range 76.1-99.9) of the net AT duration observed on the Holter recordings. AT detection was not influenced by atrial lead location. Appropriate detection of normal sinus rhythm at episode termination was 83.7% (80.7-86.3) for AT500 and 92.1% (84.5-96.2) for GEM III AT. Accurate detection and discrimination of FFRWs validates the reliability of AT diagnostic data and decreases the risk of inappropriate device therapy.
“…Israel et al confirmed AT in 35% (83 of 235) of stored mode switch episodes in 46 patients (Pulsar VDD, Guidant) 12 . Defaye et al reported appropriate detection of atrial arrhythmias in 34% of 206 stored episodes from 70 of 520 patients using a variety of devices (Guidant Discovery 1274, Pulsar 972, Pulsar Max 1270) 13 . Bordacher et al 14 reported inappropriate mode switch detection due to FFRW oversensing in 20% of 3,511 mode‐switch episodes from 137 patients (Talent DR213 PM, ELA Medical, Montrouge, France).…”
The clinical application of atrial tachyarrhythmia (AT) episode data stored by implantable devices is presently limited by the high proportion of inappropriate detection. We quantified the percentage of inappropriate AT detection in two implantable devices with AT diagnostics and therapies via meta-analysis of stored AT episodes from a number of clinical trials. The AT500 and GEM III AT, contain dual chamber logic to discriminate AT from ventricular tachycardia and far-field R wave (FFRW) oversensing using dual chamber bipolar electrograms. A subset of data from four clinical trials of 1,142 patients was considered. Manual analysis was performed on 21,553 stored episodes with atrial EGM and marker channel from 409 patients with stored episodes and the market-released device detection configuration. The percentage of episodes with inappropriate detection and termination was evaluated and compared between septal and nonseptal lead locations. The percentage of inappropriately detected episodes receiving ATP therapy was also determined. The percentage of episodes appropriately detected and the percentage of net episode duration (i.e., burden) recorded by the device were also determined from a separate analysis of 24-hour Holter recordings from a subset of 40 patients from one trial. Adjusted estimates of the percentage of appropriate [corrected] detection were 95.3% (93.5-96.7; 95% CI) for AT500 and 95.7% (84.3-98.9) for GEM III AT. Inappropriate detection was primarily due to FFRW oversensing or brief runs of premature atrial contractions (PACs). The device detected 100% of the sustained atrial arrhythmia episodes and 95.3% (range 76.1-99.9) of the net AT duration observed on the Holter recordings. AT detection was not influenced by atrial lead location. Appropriate detection of normal sinus rhythm at episode termination was 83.7% (80.7-86.3) for AT500 and 92.1% (84.5-96.2) for GEM III AT. Accurate detection and discrimination of FFRWs validates the reliability of AT diagnostic data and decreases the risk of inappropriate device therapy.
“…Current implantable pacemakers offer to the patients a better quality of life due to the existence of mathematical algorithms that aim to mimic the physiological behavior of the heart by individualized programming . They also provide the possibility of monitoring the patient’s cardiac rhythm through the intracavitary register of electrograms.…”
Section: Introductionmentioning
confidence: 99%
“…[1][2][3] The 24 hour Holter is aim to mimic the physiological behavior of the heart by individualized programming. [6][7][8][9] They also provide the possibility of monitoring the patient's cardiac rhythm through the intracavitary register of electrograms. Some authors call them as "intelligent pacemakers," because of their more precise information storage, such as electrocardiographic telemetry and event markers and counters.…”
Background: Although new pacemakers can register cardiac rhythm, few studies were performed evaluating their accuracy in diagnosing ventricular arrhythmias (VA). This study aimed to assess the correlation and agreement between the pacemaker's monitor and the ambulatory Holter in detecting VA.
Methods and results:We studied 129 patients with pacemakers, mean age 68.6 ± 19.1 years, 54.8% female. Once Holter monitoring was connected, the pacemakers' event counters were reset and clocks of both systems were synchronized to register electrocardiograms (ECG) simultaneously. Pacemakers were programmed to detect the lowest ventricular rate and lowest number of sequential beats allowed in their event monitors. After 72 hours, Holter and pacemakers records were analyzed. VA was defined in Holter and event monitor, respectively, as: isolated premature ventricular complexes: "PVC"; pairs: "couplets"; nonsustained ventricular tachycardia (NSVT):"triplets"-3 beats; "runs"-4-8 or > 8 beats, and high ventricular rates ("HVR")-3-4 beats. Spearman correlations evaluated whether pacemaker and Holter identified the same parameters. Intraclass correlation coefficients (ICCs) and respective 95% confidence intervals were calculated to assess the concordance between methods. The agreement between both systems was low, except for "triplet" and three beats NSVT (ICC = 0.984). The correlation for more than 10 PVC/h was moderate (Kappa = 0.483). When the pacemaker was programmed to detect HVR sequences of three beats lower than 140 bpm (< 140/3), the correlation with NSVT was perfect (r = 1) and agreement was also quite high (ICC = 0.800).
Conclusions:Pacemakers' event monitors underestimate the occurrence of ventricular arrhythmias detected by Holter. Standardization of pacemakers' algorithms is required before using this function for patients' clinical follow-up.
“…However, data on the proportion of patients who develop ATs during therapy with a dual chamber pacemaker show a striking discrepancy. While studies, which assessed the AT incidence on the basis of ECG recordings at scheduled or unscheduled follow‐up visits, report an annual incidence of 0.4–14%, 1,3,4 studies assessing the same endpoint based on pacemaker memory data report an incidence of 23–69% 5–9 . This may be due to the low sensitivity of serial ECG recordings, or due to the low specificity of pacemaker memory data which may count atrial sensing errors as AT.…”
Section: Introductionmentioning
confidence: 99%
“…While studies, which assessed the AT incidence on the basis of ECG recordings at scheduled or unscheduled follow-up visits, report an annual incidence of 0.4-14%, 1,3,4 studies assessing the same endpoint based on pacemaker memory data report an incidence of 23-69%. [5][6][7][8][9] This may be due to the low sensitivity of serial ECG recordings, or due to the low specificity of pacemaker memory data which may count atrial sensing errors as AT. Therefore, the precise incidence of ATs in patients with dual-chamber pacemakers remains to be determined and poses a therapeutic dilemma; for instance, regarding the need of anticoagulation therapy.…”
ATs occur in pacemaker patients significantly more frequently than estimated by ECG/Holter recordings. Only the analysis of device-stored EGMs allows reliable assessment of the AT burden.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.